Experienced in Developmental Dysphasia Familial

Michael Jonsson

Goeteborg, O, SE 
Experienced in Developmental Dysphasia Familial
Goeteborg, O, SE 
OverviewLocationsClinical Research

Overview

Michael Jonsson practices in Goeteborg, Sweden. Mr. Jonsson is rated as an Experienced expert by MediFind in the treatment of Developmental Dysphasia Familial. His top areas of expertise are Vascular Dementia, Primary Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), and CACH Syndrome.

His clinical research consists of co-authoring 16 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Developmental Dysphasia Familial.

Gender
Male

Locations

Goeteborg, O, Sweden
Other Locations
Moelndal, O, Sweden

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase Ib/IIa Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Doses, Regimens and Combinations of Tau Targeted Vaccines in Subjects With Early Alzheimer's Disease
A Phase Ib/IIa Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Doses, Regimens and Combinations of Tau Targeted Vaccines in Subjects With Early Alzheimer's Disease
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Other, Biological
Study Drugs: ACI-35.030 Anti-Tau Vaccine, JACI-35.054 Anti-Tau Vaccine
Study Phase: Phase 1/Phase 2

16 Total Publications

Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase 1b/2a, multicentre, double-blind, randomised, placebo-controlled study.
Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase 1b/2a, multicentre, double-blind, randomised, placebo-controlled study.
Journal: EBioMedicine
Published: February 20, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Jonsson's expertise for a condition
ConditionClose
      View All 7 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile